ストックスクリーナーアプリを入手
50.21
50.55%
-51.32
前日終値:
$101.53
開ける：
$49.66
24時間の取引高:
15.43M
Relative Volume:
13.80
時価総額：
$1.96B
収益：
$117.67M
当期純損益:
$-1.88B
株価収益率:
-0.8294
EPS:
-60.5369
ネットキャッシュフロー:
$-621.36M
1週間 パフォーマンス:
-48.50%
1か月 パフォーマンス:
-50.44%
6か月 パフォーマンス:
+56.08%
1年 パフォーマンス:
+5.13%
1日の値動き範囲:
$48.00
$56.75
1週間の範囲:
$48.00
$109.05
52週間の値動き範囲:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
50.21 | 3.96B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | 開始されました | TD Cowen | Hold |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-11-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-10-17 | 開始されました | Guggenheim | Neutral |
すべてを表示
Grail Inc (GRAL) 最新ニュース
Grail’s Cancer Detection Test Fails in Major Study — What It Means for the Future of Early Cancer Screening - vocal.media
GRAIL Stock: A Major Trial Disappointment (NASDAQ:GRAL) - Seeking Alpha
GRAIL (-51%): NHS-Galleri Trial Misses Primary Endpoint, Erasing Value - Trefis
Grail Trial Setback Raises Questions Over Multi-Cancer Blood Screening Outlook - TipRanks
TD Cowen reiterates Hold on Grail stock after study setback By Investing.com - Investing.com Nigeria
Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main Goal - GuruFocus
5 Analysts Assess GRAIL: What You Need To Know - Benzinga
This once-hot cancer-detection company’s stock got cut in half after a failed trial - MarketWatch
These Stocks Are Today’s Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More - Barron's
Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip? - Yahoo Finance
Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% - MedCity News
Grail’s multi-cancer early detection test misses study goal - BioPharma Dive
Trouble Continues for Grail as Stock Falls After Cancer Blood Test Trial Fails to Meet Endpoint - Medical Device and Diagnostic industry
Grail, Corning, Comfort Systems USA, Opendoor, Akamai, and More Market Movers - Barron's
After rallying, Grail's cancer test faces new uncertainty due to UK study - Endpoints News
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD - GlobeNewswire
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire Inc.
GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions - TechStock²
Here's Why Grail Stock Crashed 50% Today - Yahoo Finance
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
Why Grail Stock Has Plunged 50% Despite Earnings Beat - Barron's
Grail Stock Plunges 50% After Earnings. Test Results Are to Blame. - Barron's
These Stocks Are Today’s Movers: Grail, Corning, Opendoor, Akamai, AppLovin, Chemours, and More - Barron's
Grail shares plummet after UK study raises doubts over cancer test's prospects - marketscreener.com
Baird Lowers Price Target for GRAIL (GRAL) to $82, Maintains Out - GuruFocus
Canaccord Genuity cuts Grail stock price target on trial results By Investing.com - Investing.com India
Relative Strength Alert For Grail - Nasdaq
GRAIL Inc (GRAL) Trading Down 46.11% on Feb 20 - GuruFocus
Grail shares plunge after Galleri test misses primary endpoint - bioworld.com
These stocks are today’s movers: Grail, AppLovin, Nvidia, Opendoor, Akamai, Newmont, Copart, and more - MSN
Grail shares plummet after cancer test falls short in three-year NHS study - firstwordpharma.com
Grail, Wayfair, Crocs, AppLovin, Opendoor, Akamai, Newmont, and More Market Movers - Barron's
Grail shares sink after cancer-screening trial disappointment - Sharecast.com
Stock market today: Dow Jones, S&P 500 futures rise ahead of Q4 GDP numbers—Grail, Candel Therapeutics, Copart in focus - MSN
Biotech Stock Plummets on Cancer Screening Trial Results - Schaeffer's Investment Research
TD Cowen reiterates Hold on Grail stock after study setback - Investing.com
Grail (GRAL) Stock Crashes as Q4 Earnings Beat Overshadowed by Cancer Trial Results - parameter.io
GRAIL's NHS-Galleri Trial Falls Short Of Primary Endpoint In Multi-Cancer Screening, Shares Slide - Nasdaq
Element Biosciences launches table-top sequencer capable of $100 genome - statnews.com
Canaccord Genuity cuts Grail stock price target on trial results - Investing.com
Stock Movers: Blue Owl, Grail, Opendoor - Bloomberg
Pharmalittle: We're reading about an FDA official's speech, a Grail cancer blood test, and much more - statnews.com
Cancer Test Company Stock Crashes After Clinical Trial Falls Short - Fine Day 102.3
Grail’s Cancer Detection Test Fails in Major Study - The New York Times
Grail tanks after cancer detection test fails in key study - Sherwood News
GRAL Inc. Faces Market Volatility Amid Earnings Announcement - timothysykes.com
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) - Benzinga
Grail (GRAL) Stock: Why the Biotech Crashed 50% Overnight - Blockonomi
Grail shares plunge after major cancer screening trial misses main goal - marketscreener.com
Grail's multi-cancer test fluffs its lines in UK trial - pharmaphorum
Analysis of Stock Price Movements for Multiple Companies - Intellectia AI
Grail Inc (GRAL) 財務データ
収益
当期純利益
現金流量
EPS
0.01%
0.07%
大文字化:
|
ボリューム (24 時間):